|Day Low/High||127.18 / 130.95|
|52 Wk Low/High||111.30 / 138.87|
Stocks enjoy their biggest gains since the beginning of March after centrist Emmanuel Macron wins the first round of the country's presidential elections over far-right Marine Le Pen.
Pet costs are seen surging, as are several other top household categories.
TheStreet's Jim Cramer said Kimberly Clark's KMB latest results were a little subdued.
TheStreet's Jim Cramer weighs in on Becton Dickinson BDX, Kimberly Clark KMB, Caterpillar CAT, Chipotle CMG, 3M and the possibility of a government shutdown.
Kimberly-Clark reported somewhat disappointing earnings, but buying for the long-term is still a good idea, Cramer said.
Stocks rocket higher on Monday after centrist Emmanuel Macron wins the first round of the country's presidential elections over far-right Marine Le Pen.
Stock futures rocket higher on Monday after centrist Emmanuel Macron wins the first round of the country's presidential elections over far-right Marine Le Pen.
U.S. stock futures are set for solid gains and European stocks soar after the first round of France's elections put centrist Emmanuel Macron in the lead for the presidency.
But also remember that this week earnings will run wild, with nearly 200 members of the S&P 500 reporting.
Here are five things you must know for Monday, April 24.
Doug Kass shares his thoughts on Macy's, Kohl's and Walmart.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.
Jefferies began coverage of Kimberly Clark on Tuesday.
Here are Tuesday's top research calls, including new coverage of Colgate-Palmolive, Clorox and Splunk, a downgrade for Cummins and an upgrade for McDonald's.
Doug Kass shares his thoughts on Twitter and talks about Sears.
Here are Friday's top research calls, including upgrades for IberiaBank and Actuant, and downgrades for Kimberly-Clark and Ionis Pharma.